[Skip to Navigation]
Invited Commentary
January 2018

The Role of Lipoprotein(a) in Calcific Aortic Valve Disease: Insights From a Large-Cohort Genetic Study

Author Affiliations
  • 1Center for Cardiovascular Research, Nationwide Children’s Hospital, Columbus, Ohio
  • 2The Heart Center, Nationwide Children’s Hospital, Columbus, Ohio
  • 3Department of Pediatrics, The Ohio State University, Columbus
  • 4Department of Molecular Genetics, The Ohio State University, Columbus
JAMA Cardiol. 2018;3(1):24-25. doi:10.1001/jamacardio.2017.4267

Because the elderly population continues to grow, calcific aortic valve disease (CAVD) is becoming an increasingly prevalent cardiovascular disease. Calcific aortic valve disease is characterized by calcium deposits on the arterial aspect of the aortic valve, which leads to stiffness of the valve cusps and narrowing of the valve orifice; this is diagnosed as aortic valve stenosis (AVS), the clinical manifestation of CAVD. Treatment options are limited to surgical or catheter-based aortic valve replacement for severe disease. Because prevalence is an estimated 2% to 7% in individuals older than 65 years,1 investigations of effective medical therapies to slow or halt the progression of disease are vital.

Add or change institution